儿童间质性和弥漫性肺疾病的肺部适配体特征
该研究利用SOMAmer适配体技术检测儿童间质性和弥漫性肺疾病(chILD)患儿支气管肺泡灌洗液(BALF)中1129种蛋白水平,发现神经内分泌细胞增生症(NEHI)患儿有202种适配体与对照组显著不同,表面活性物质突变患儿有51种显著不同,并识别出NEHI的两种内型。
要点
- NEHI患儿BALF中202种适配体水平与对照组显著不同(P<0.05)。
- 表面活性物质突变患儿BALF中51种适配体水平与对照组显著不同(P<0.05)。
- 肺纤维化和炎症相关蛋白与表面活性物质功能障碍组相关,而与NEHI组无关。
核心结论
- 从chILD患儿BALF中可确定不同的蛋白质和蛋白质通路,有望加深对chILD的理解。
研究设计与样本
- 研究纳入chILD患儿和疾病对照,采用标准化方案收集BALF并储存长达10年。
- 使用适配体检测法测量BALF上清中1129种蛋白质水平。
- NEHI组22例,表面活性物质突变组8例,对照组9例。
主要发现
- NEHI患儿(n=22)有202种适配体在BALF中与对照组(n=9)显著不同(P<0.05)。
- 表面活性物质突变患儿(n=8)有51种适配体在BALF中与对照组(n=9)显著不同(P<0.05)。
- 肺纤维化和炎症相关蛋白与表面活性物质功能障碍组相关,而与NEHI组无关。
- 层次聚类分析识别出两种不同的NEHI内型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Biomarker signatures are needed in children with children's interstitial and diffuse lung disease (chILD) to improve diagnostic approaches, increase our understanding of disease pathogenesis, monitor disease progression, and develop new treatment strategies. Proteomic technology using SOMAmer (Slow Off-rate Modified Aptamer) nucleic acid-based protein-binding reagents allows for biomarker discovery.Objectives: We hypothesized that proteins and protein pathways in BAL fluid (BALF) would distinguish children with neuroendocrine cell hyperplasia of infancy (NEHI), surfactant dysfunction mutations, and other chILD diagnoses and control subjects.Methods: BALF was collected for clinical indications and banked in patients with chILD and disease control subjects using standardized protocols over 10 years. BALF supernatant was analyzed using an aptamer assay to measure 1,129 protein levels. Protein levels were compared between groups using an ANOVA and adjusted for multiple comparisons using false discovery rate. Proteins were classified into pathways. Hierarchical clustering was used to define endotypes in the group of children with NEHI.Measurements and Main Results: After correcting for multiple testing, children with NEHI (n = 22) had 202 aptamers that were significantly different (P < 0.05) in BALF compared with control subjects (n = 9). Children with surfactant mutation (n = 8) had 51 aptamers significantly different (P < 0.05) in BALF compared with control subjects (n = 9). Proteins associated with pulmonary fibrosis and inflammation were associated with the surfactant dysfunction group but not the NEHI group. Using hierarchical clustering analysis, two distinct NEHI endotypes were identified.Conclusions: Distinct proteins and protein pathways can be determined from BALF of children with chILD, and these hold promise to further our understanding of chILD.
引用
- Deterding RR, Wagner BD, Harris JK, et al. Pulmonary Aptamer Signatures in Children's Interstitial and Diffuse Lung Disease. Am J Respir Crit Care Med. 2019. PMID: 31409098. doi:10.1164/rccm.201903-0547OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。